Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes (2014 - 2020)

Enanta Pharmaceuticals posted quarterly Deferred Taxes of $15.0 million for Q3 2020, up 1363.63% year-on-year from $1.0 million in Q4 2019, and up 576.58% on a QoQ basis from -$3.1 million in Q2 2020.

Enanta Pharmaceuticals (ENTA) has 7 years of Deferred Taxes data on file, last reported at $15.0 million in Q3 2020.

  • For the quarter ending Q3 2020, Deferred Taxes rose 1363.63% year-over-year to $15.0 million; the trailing twelve-month figure through Sep 2020 stood at $10.6 million (up 438.05% YoY), and the FY2021 full-year result was $345000.0, down 96.75% from the prior year.
  • Deferred Taxes for Q3 2020 stood at $15.0 million, up from -$3.1 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $15.0 million in Q3 2020 and bottomed at -$3.8 million in Q2 2017.
  • The 5-year median for Deferred Taxes is -$918000.0 (2018), against an average of $263052.6.
  • The widest annual swing landed in 2016, when Deferred Taxes tumbled 5816.67%; it then soared 1363.63% in 2020.
  • A 5-year view of Deferred Taxes shows it stood at -$1.9 million in 2016, then soared by 239.37% to $2.7 million in 2017, then tumbled by 134.49% to -$918000.0 in 2018, then soared by 171.57% to $657000.0 in 2019, then jumped by 2179.15% to $15.0 million in 2020.
  • The last three Deferred Taxes figures came in at $15.0 million (Q3 2020), -$3.1 million (Q2 2020), and -$1.9 million (Q1 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -859,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -65.30 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 96.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 9.31 Mn
10 Enanta Pharmaceuticals 367.22 Mn 203.44 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 14.97 Mn
Jun 30, 2020 -3.14 Mn
Mar 31, 2020 -1.88 Mn
Dec 31, 2019 657,000.00
Sep 30, 2019 -1.19 Mn
Jun 30, 2019 -1.15 Mn
Mar 31, 2019 118,000.00
Dec 31, 2018 -918,000.00
Sep 30, 2018 -495,000.00
Jun 30, 2018 -438,000.00
Mar 31, 2018 129,000.00
Dec 31, 2017 2.66 Mn
Sep 30, 2017 7.59 Mn
Jun 30, 2017 -3.80 Mn
Mar 31, 2017 -3.53 Mn
Dec 31, 2016 -1.91 Mn
Sep 30, 2016 -2.84 Mn
Jun 30, 2016 1.27 Mn
Mar 31, 2016 -1.10 Mn
Dec 31, 2015 382,000.00
Sep 30, 2015 -48,000.00
Jun 30, 2015 -788,000.00
Mar 31, 2015 377,000.00
Dec 31, 2014 11.49 Mn
Sep 30, 2014 17,000.00